Celltrion
Celltrion is a South Korean biopharmaceutical company headquartered in Incheon, South Korea. It was founded in 2002 by Jung Jin Seo. The company specializes in the development, manufacturing, and marketing of biosimilars and biopharmaceuticals. Celltrion is known for its innovative approach to biotechnology and has made significant contributions to the global healthcare industry.
History[edit]
Celltrion was established in 2002 with the aim of developing biosimilars, which are biologic medical products highly similar to already approved reference products. The company quickly gained recognition for its high-quality biosimilars and expanded its operations globally.
Products[edit]
Celltrion's product portfolio includes a range of biosimilars and biopharmaceuticals. Some of the notable products include:
- Remsima (infliximab): A biosimilar to Remicade, used to treat autoimmune diseases such as rheumatoid arthritis and Crohn's disease.
- Truxima (rituximab): A biosimilar to Rituxan, used in the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
- Herzuma (trastuzumab): A biosimilar to Herceptin, used in the treatment of HER2-positive breast cancer.
Research and Development[edit]
Celltrion invests heavily in research and development (R&D) to innovate and improve its product offerings. The company operates state-of-the-art R&D facilities and collaborates with various academic and research institutions to advance its biopharmaceutical technologies.
Global Presence[edit]
Celltrion has a strong global presence, with subsidiaries and partnerships in various countries. The company exports its products to numerous markets, including the United States, Europe, and Asia. Celltrion's global expansion strategy focuses on increasing accessibility to affordable biosimilars and improving healthcare outcomes worldwide.
Awards and Recognition[edit]
Celltrion has received numerous awards and accolades for its contributions to the biopharmaceutical industry. The company is recognized for its commitment to quality, innovation, and patient care.
See Also[edit]
- Biopharmaceutical
- Biosimilar
- Incheon
- Rheumatoid arthritis
- Crohn's disease
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
- HER2-positive breast cancer
References[edit]
External Links[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
